Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.
Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.
Azar Alex M II reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health director Azar Alex M II received a grant of 2,711 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of common stock for no cash payment. The award vests in full on June 17, 2026, the one-year anniversary of the grant date, or on the date of Guardant Health’s next annual meeting of stockholders, whichever occurs earlier. Following this Form 4 transaction, Azar holds 2,711 RSUs directly.
Guardant Health filed a Form 144 disclosing restricted stock lapses and related sales by an individual. The filing lists three reported transactions by Musa Tariq on 04/16/2026 (9,840.00), 05/18/2026 (11,131.00), and 06/16/2026 (15,102.00) tied to equity compensation and a restricted stock lapse dated 06/18/2026.
Guardant Health, Inc. notice of proposed sales under Form 144 by an affiliate. The filing lists an employee stock option exercise of 2,000 shares settled via a broker payment for a cashless exercise on 06/22/2026, a restricted stock lapse of 4,203 shares on 06/17/2026, and a reported sale of 10,000 shares on 06/03/2026 for $1,269,809.00.
Guardant Health, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected all director nominees, including Ian Clark with 70,526,891 votes for and Manuel Hidalgo Medina with 81,925,123 votes for, with broker non-votes recorded on each.
Stockholders approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 115,899,030 votes for. An advisory vote to approve compensation of named executive officers was not approved, receiving 98,236,639 votes for and 9,905,190 votes against. In an advisory vote on the frequency of future say-on-pay votes, most votes were cast for one year, with 107,997,996 votes for that option.
Guardant Health Chief Information Officer Kumud Kalia reported routine stock-based compensation activity. On June 15, 2026, 638 restricted stock units converted into common shares, while 314 shares were withheld by the company to cover tax obligations. After these transactions, Kalia directly holds 41,414 common shares.
Guardant Health director Tariq Musa reported a small mix of stock transactions involving company shares. On June 15, 2026, a restricted stock unit (RSU) award converted into 250 shares of common stock at a stated price of $0.00 per share, reflecting vesting of previously granted equity compensation.
The same RSU award was originally granted on March 6, 2023 and vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over three years. On June 16, 2026, Musa executed an open-market sale of 116 shares of common stock at an average price of $130.19 per share. Following these transactions, he holds 8,796 shares of Guardant Health common stock directly.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity on June 15, 2026. He exercised 1,020 restricted stock units into common shares, then had 535 of those shares withheld by the company at $129.82 per share to cover tax obligations, with no open-market sale. After these transactions, Saia directly holds 36,435 Guardant Health shares. The RSU award was granted on June 9, 2023 and vests over three years, with 33% vesting on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported routine equity compensation activity involving restricted stock units and common stock. On June 15, 2026, 1,402 restricted stock units were converted into an equal number of common shares as part of a previously granted award that vested over a three-year period.
To cover related tax obligations on this vesting, the company retained 594 common shares at a price of $129.82 per share, a non-market tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly held 61,101 common shares of Guardant Health.